{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:44:57Z","timestamp":1765370697009,"version":"3.41.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00520-025-09531-5","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:27:35Z","timestamp":1747207655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of the usefulness of protocol-based magnesium supplementation for hypomagnesemia in patients with advanced or recurrent colorectal cancer treated with panitumumab"],"prefix":"10.1007","volume":"33","author":[{"given":"Daisuke","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiseki","family":"Usami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"9531_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","volume":"15","author":"TJ Price","year":"2014","unstructured":"Price TJ, Peeters M, Kim TW et al (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15:569\u2013579. https:\/\/doi.org\/10.1016\/S1470-2045(14)70118-4","journal-title":"Lancet Oncol"},{"key":"9531_CR2","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer. J Clin Oncol 25:1658\u20131664. https:\/\/doi.org\/10.1200\/JCO.2006.08.1620","journal-title":"J Clin Oncol"},{"key":"9531_CR3","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706\u20134713. https:\/\/doi.org\/10.1200\/JCO.2009.27.6055","journal-title":"J Clin Oncol"},{"key":"9531_CR4","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J et al (2010) Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697\u20134705. https:\/\/doi.org\/10.1200\/JCO.2009.27.4860","journal-title":"J Clin Oncol"},{"key":"9531_CR5","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1007\/s13277-014-2983-9","volume":"36","author":"Q Wang","year":"2015","unstructured":"Wang Q, Qi Y, Zhang D et al (2015) Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumour Biol 36:3471\u20133482. https:\/\/doi.org\/10.1007\/s13277-014-2983-9","journal-title":"Tumour Biol"},{"key":"9531_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3816\/CCC.2006.n.033","volume":"6","author":"MG Fakih","year":"2006","unstructured":"Fakih MG, Wilding G, Lombardo J (2006) Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 6:152\u2013156. https:\/\/doi.org\/10.3816\/CCC.2006.n.033","journal-title":"Clin Colorectal Cancer"},{"key":"9531_CR7","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00280-016-3039-1","volume":"77","author":"H Fujii","year":"2016","unstructured":"Fujii H, Iihara H, Suzuki A et al (2016) Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol 77:1209\u20131215. https:\/\/doi.org\/10.1007\/s00280-016-3039-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"9531_CR8","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/s41598-018-19835-8","volume":"8","author":"MC Hsieh","year":"2018","unstructured":"Hsieh MC, Wu CF, Chen CW et al (2018) Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis. Sci Rep 8:2047. https:\/\/doi.org\/10.1038\/s41598-018-19835-8","journal-title":"Sci Rep"},{"key":"9531_CR9","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/annonc\/mdq550","volume":"22","author":"B Vincenzi","year":"2011","unstructured":"Vincenzi B, Galluzzo S, Santini D et al (2011) Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann Oncol 22:1141\u20131146. https:\/\/doi.org\/10.1093\/annonc\/mdq550","journal-title":"Ann Oncol"},{"key":"9531_CR10","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/annonc\/mds577","volume":"24","author":"MM Vickers","year":"2013","unstructured":"Vickers MM, Karapetis CS, Tu D et al (2013) Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG\/AGITG CO.17. Ann Oncol 24:953\u2013960. https:\/\/doi.org\/10.1093\/annonc\/mds577","journal-title":"Ann Oncol"},{"key":"9531_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00280-020-04126-9","volume":"86","author":"M Kimura","year":"2020","unstructured":"Kimura M, Usami E, Teramachi H et al (2020) Identifying optimal magnesium replenishment points based on risk of severe hypomagnesemia in colorectal cancer patients treated with cetuximab or panitumumab. Cancer Chemother Pharmacol 86:383\u2013391. https:\/\/doi.org\/10.1007\/s00280-020-04126-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"9531_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.5649\/jjphcs.37.403","volume":"37","author":"E Nakamoto","year":"2011","unstructured":"Nakamoto E, Kawakami K, Imada H et al (2011) Retrospective investigation on cetuximab-induced hypomagnesemia; incidence, time of onset, and management. Jpn J Pharm Health Care Sci 37:403\u2013409. https:\/\/doi.org\/10.5649\/jjphcs.37.403","journal-title":"Jpn J Pharm Health Care Sci"},{"key":"9531_CR13","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/j.clcc.2016.02.011","volume":"15","author":"DM Jiang","year":"2016","unstructured":"Jiang DM, Dennis K, Steinmetz A et al (2016) Management of epidermal growth factor receptor inhibitor-induced hypomagnesemia: a systematic review. Clin Colorectal Cancer 15:e117\u2013e123. https:\/\/doi.org\/10.1016\/j.clcc.2016.02.011","journal-title":"Clin Colorectal Cancer"},{"key":"9531_CR14","first-page":"897","volume":"40","author":"M Demizu","year":"2013","unstructured":"Demizu M, Ueda H, Osawa M et al (2013) Effect of magnesium supplementation on early-stage hypomagnesemia in patients treated with cetuximab. Gan To Kagaku Ryoho 40:897\u2013900","journal-title":"Gan To Kagaku Ryoho"},{"key":"9531_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.443","volume":"4","author":"A Awan","year":"2021","unstructured":"Awan A, Basulaiman B, Stober C et al (2021) Oral magnesium supplements for cancer treatment-induced hypomagnesemia: results from a pilot randomized trial. Health Sci Rep 4:e443. https:\/\/doi.org\/10.1002\/hsr2.443","journal-title":"Health Sci Rep"},{"key":"9531_CR16","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1248\/bpb.b23-00714","volume":"47","author":"R Matsukane","year":"2024","unstructured":"Matsukane R, Isshiki R, Suetsugu K et al (2024) Risk factors of cetuximab-induced hypomagnesemia and the effect of magnesium prophylaxis in patients with head and neck cancer: a retrospective study. Biol Pharm Bull 47:732\u2013738. https:\/\/doi.org\/10.1248\/bpb.b23-00714","journal-title":"Biol Pharm Bull"},{"key":"9531_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"9531_CR18","first-page":"574","volume":"85","author":"A Ikari","year":"2013","unstructured":"Ikari A (2013) Molecular mechanism of magnesium transport in renal tubule. Seikagaku 85:574\u2013577","journal-title":"Seikagaku"},{"key":"9531_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(07)70108-0","volume":"8","author":"S Tejpar","year":"2007","unstructured":"Tejpar S, Piessevaux H, Claes K et al (2007) Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 8:387\u2013394. https:\/\/doi.org\/10.1016\/S1470-2045(07)70108-0","journal-title":"Lancet Oncol"},{"key":"9531_CR20","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1172\/JCI33004","volume":"117","author":"S Muallem","year":"2007","unstructured":"Muallem S, Moe OW (2007) When EGF is offside, magnesium is wasted. J Clin Invest 117:2086\u20132089. https:\/\/doi.org\/10.1172\/JCI33004","journal-title":"J Clin Invest"},{"key":"9531_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1200\/OP.23.00660","volume":"20","author":"W Liu","year":"2024","unstructured":"Liu W, Meyer L, Morse M et al (2024) Dietary magnesium replacement for prevention of hypomagnesemia in patients with ovarian cancer receiving carboplatin-based chemotherapy. JCO Oncol Pract 20:517\u2013524. https:\/\/doi.org\/10.1200\/OP.23.00660","journal-title":"JCO Oncol Pract"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09531-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09531-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09531-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T18:02:59Z","timestamp":1749492179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09531-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["9531"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09531-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"12 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki of 1964 and its subsequent amendments, or equivalent ethical standards and ethical guidelines for human life science and medical research. The study protocol was approved by the Institutional Review Board of the Ogaki Municipal Hospital (Ogaki, Japan; approval number 20240328\u201318). Comprehensive informed consent was obtained from the participants by displaying an opt-out option on our website.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Comprehensive informed consent was obtained from the participants by displaying an opt-out option on our website.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"472"}}